Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 7.36
SNTA's Cash to Debt is ranked higher than
67% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. SNTA: 7.36 )
SNTA' s 10-Year Cash to Debt Range
Min: 2.27   Max: No Debt
Current: 7.36

F-Score: 3
Z-Score: -3.40
M-Score: -4.03
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -173.25
SNTA's ROE (%) is ranked higher than
54% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. SNTA: -173.25 )
SNTA' s 10-Year ROE (%) Range
Min: -2635.13   Max: -47.15
Current: -173.25

-2635.13
-47.15
ROA (%) -94.98
SNTA's ROA (%) is ranked higher than
54% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. SNTA: -94.98 )
SNTA' s 10-Year ROA (%) Range
Min: -2607.57   Max: 108.22
Current: -94.98

-2607.57
108.22
ROC (Joel Greenblatt) (%) -6389.73
SNTA's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. SNTA: -6389.73 )
SNTA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6421.64   Max: 1600.97
Current: -6389.73

-6421.64
1600.97
Revenue Growth (%) -100.00
SNTA's Revenue Growth (%) is ranked higher than
53% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. SNTA: -100.00 )
SNTA' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 164.5
Current: -100

0
164.5
EBITDA Growth (%) 12.20
SNTA's EBITDA Growth (%) is ranked higher than
87% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. SNTA: 12.20 )
SNTA' s 10-Year EBITDA Growth (%) Range
Min: -29.9   Max: 158.9
Current: 12.2

-29.9
158.9
EPS Growth (%) 10.90
SNTA's EPS Growth (%) is ranked higher than
85% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. SNTA: 10.90 )
SNTA' s 10-Year EPS Growth (%) Range
Min: -37.2   Max: 166.5
Current: 10.9

-37.2
166.5
» SNTA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

SNTA Guru Trades in Q4 2013

Louis Moore Bacon 115,000 sh (New)
Jim Simons 214,000 sh (New)
Steven Cohen Sold Out
» More
Q1 2014

SNTA Guru Trades in Q1 2014

John Burbank 46,620 sh (New)
Murray Stahl 11,000 sh (New)
Louis Moore Bacon Sold Out
Jim Simons Sold Out
» More
Q2 2014

SNTA Guru Trades in Q2 2014

Murray Stahl 11,000 sh (unchged)
John Burbank Sold Out
» More
Q3 2014

SNTA Guru Trades in Q3 2014

Jim Simons 377,275 sh (New)
Murray Stahl 11,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with SNTA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2014-06-30 Sold Out 0.01%$3.97 - $4.48 $ 3.13-25%0
John Burbank 2014-03-31 New Buy0.01%$4.28 - $7.01 $ 3.13-44%46620
Jean-Marie Eveillard 2012-06-30 Sold Out 0.0035%$3.68 - $7.82 $ 3.13-33%0
Jean-Marie Eveillard 2012-03-31 New Buy$4.22 - $5.66 $ 3.13-30%200000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.10
SNTA's P/B is ranked higher than
78% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. SNTA: 4.10 )
SNTA' s 10-Year P/B Range
Min: 2.91   Max: 28.34
Current: 4.1

2.91
28.34
EV-to-EBIT -2.77
SNTA's EV-to-EBIT is ranked higher than
70% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SNTA: -2.77 )
SNTA' s 10-Year EV-to-EBIT Range
Min: -12.2   Max: 2.2
Current: -2.77

-12.2
2.2
Current Ratio 3.71
SNTA's Current Ratio is ranked higher than
68% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. SNTA: 3.71 )
SNTA' s 10-Year Current Ratio Range
Min: 0.43   Max: 7.01
Current: 3.71

0.43
7.01
Quick Ratio 3.71
SNTA's Quick Ratio is ranked higher than
69% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. SNTA: 3.71 )
SNTA' s 10-Year Quick Ratio Range
Min: 0.43   Max: 7.01
Current: 3.71

0.43
7.01

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.28
SNTA's Price/Net Cash is ranked higher than
91% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 64.50 vs. SNTA: 4.28 )
SNTA' s 10-Year Price/Net Cash Range
Min: 3.46   Max: 80.9
Current: 4.28

3.46
80.9
Price/Net Current Asset Value 4.28
SNTA's Price/Net Current Asset Value is ranked higher than
90% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. SNTA: 4.28 )
SNTA' s 10-Year Price/Net Current Asset Value Range
Min: 3.46   Max: 80.9
Current: 4.28

3.46
80.9
Price/Tangible Book 4.06
SNTA's Price/Tangible Book is ranked higher than
83% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. SNTA: 4.06 )
SNTA' s 10-Year Price/Tangible Book Range
Min: 3.07   Max: 30.05
Current: 4.06

3.07
30.05
Earnings Yield (Greenblatt) -36.10
SNTA's Earnings Yield (Greenblatt) is ranked higher than
52% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. SNTA: -36.10 )
SNTA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 45.1   Max: 1539.2
Current: -36.1

45.1
1539.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:YDO.Germany
Synta Pharmaceuticals Inc was incorporated in Delware in March 2000 and commenced operations in July 2001. The Company is a biopharmaceutical company, engaged in discovering, developing and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Its drug candidate, ganetespib, is a next generation Hsp90 inhibitor in Phase 3 development for non-small cell lung cancer (NSCLC) and in development program, including clinical trials for breast cancer, ovarian cancer and acute myeloid leukemia. In addition, It is developing a unique, proprietary platform for enhanced delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Its drug candidates and preclinical compounds are small molecules that can be readily synthesized by processes that it has developed. Its patent portfolio has a total of 906 patents and patent applications worldwide. With respect to its Hsp90 inhibitor program, it has 112 issued U.S. and foreign patents, and 154 pending U.S. and foreign counterpart patent applications.
» More Articles for SNTA

Headlines

Articles On GuruFocus.com
Top 4 Insider Buys of Last Week Jun 10 2013 
Weekly CEO Buys Highlight: SNTA, MEI, PZG, MCHX, CMXI Jul 07 2012 
Weekly CEO Buys Highlight: SNTA, MEI, PZG, MCHX, CMXI Jul 07 2012 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 
Synta Pharmaceuticals Inc. (SNTA) CEO Safi R Bahcall buys 5,000 Shares Mar 15 2011 
Synta Pharmaceuticals Inc. (SNTA) VP, Fin. and Admin., CFO Keith S Ehrlich sells 2,537 Shares Mar 03 2011 
MAGIC FORMULA INVESTING 2010 YEAR IN REVIEW -- Winners: MGIC, QCOR, SNTA, CF; Losers: SPMD, JTX Jan 01 2011 
Synta Pharmaceuticals Inc. (SNTA) CEO Safi R Bahcall buys 10,000 Shares Jun 10 2010 
Synta Pharmaceuticals Inc. (SNTA) CEO Safi R Bahcall buys 22,222 Shares Jan 12 2010 
Synta Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2009 

More From Other Websites
Synta Announces Presentation on Hsp90 inhibitor Drug Conjugate Platform at 26th EORTC-NCI-AACR... Nov 19 2014
SYNTA PHARMACEUTICALS CORP Financials Nov 15 2014
Synta to Present at the Stifel 2014 Healthcare Conference Nov 12 2014
Synta to Present at the Stifel 2014 Healthcare Conference Nov 12 2014
10-Q for Synta Pharmaceuticals Corp. Nov 09 2014
Synta Pharmaceuticals Corp Earnings Call scheduled for 10:00 am ET today Nov 06 2014
Synta beats 3Q profit forecasts Nov 06 2014
Synta beats 3Q profit forecasts Nov 06 2014
Synta Reports Third Quarter Financial Results and Provides Corporate Update Nov 06 2014
Q3 2014 Synta Pharmaceuticals Corp Earnings Release - Before Market Open Nov 06 2014
Synta Reports Third Quarter Financial Results and Provides Corporate Update Nov 06 2014
SYNTA PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report Nov 06 2014
Will Synta Pharmaceuticals (SNTA) Post a Wider Q3 Loss? Nov 05 2014
Synta Announces FDA’s Oncologic Drugs Advisory Committee to Discuss Pediatric Uses for Ganetespib Nov 05 2014
Synta Announces FDA’s Oncologic Drugs Advisory Committee to Discuss Pediatric Uses for Ganetespib Nov 05 2014
Synta Announces Initiation of I-SPY 2 TRIAL of Ganetespib in Breast Cancer Oct 29 2014
Synta Announces Initiation of I-SPY 2 TRIAL of Ganetespib in Breast Cancer Oct 29 2014
Synta to Host Conference Call and Webcast of Third Quarter 2014 Financial Results on November 6,... Oct 27 2014
Synta to Host Conference Call and Webcast of Third Quarter 2014 Financial Results on November 6,... Oct 27 2014
Synta Reports Inducement Grant to New Chief Executive Officer Sep 04 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK